References
  1. Silvey M, Brandão LR. Risk Factors, Prophylaxis, and Treatment of Venous Thromboembolism in Congenital Heart Disease Patients. Front Pediatr . 2017;5:146. Published 2017 Jun 19. doi:10.3389/fped.2017.00146
  2. Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association [published correction appears in Circulation. 2014 Jan 14;129(2):e23]. Circulation . 2013;128:2622-2703. doi:10.1161/01.cir.0000436140.77832.7a
  3. Velleca A, Shullo MA, Dhital K et al. The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients, The Journal of Heart and Lung Transplantation, 2022, ISSN 1053-2498, https://doi.org/10.1016/j.healun.2022.09.023.
  4. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-962. doi:10.1016/S0140-6736(13)62343-0
  5. Alcalai R, Butnaru A, Moravsky G, et al. Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial‡. Eur Heart J Cardiovasc Pharmacother . 2022;8:660-667. doi:10.1093/ehjcvp/pvab057
  6. Kumar D, Warsha FNU, Helmstetter N, Gupta V. Efficacy and safety of direct oral anticoagulants for treatment of left ventricular thrombus; a systematic review. Acta Cardiol. 2021;76:825-829. doi:10.1080/00015385.2021.1901024
  7. Kazerouninia A, Georgekutty J, Kendsersky P, et al. A Multisite Retrospective Review of Direct Oral Anticoagulants Compared to Warfarin in Adult Fontan Patients [published online ahead of print, 2022 Jan 13]. Cardiovasc Drugs Ther . 2022;10.1007/s10557-021-07298-5. doi:10.1007/s10557-021-07298-5
  8. Mills K, Hill C, King M, et al. Just DOAC: Use of direct-acting oral anticoagulants in pediatrics [published online ahead of print, 2023 Jan 5]. Am J Health Syst Pharm . 2023;zxac387. doi:10.1093/ajhp/zxac387
  9. Dunois C. Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). Biomedicines. 2021 Apr 21;9:445. doi: 10.3390/biomedicines9050445. PMID: 33919121; PMCID: PMC8143174.
  10. O’Brien SH, Li D, Mitchell LG, et al. PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design. Thromb Haemost . 2019;119:844-853. doi:10.1055/s-0039-1679938
  11. Payne RM, Burns KM, Glatz AC, et al. A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study. Am Heart J . 2019;217:52-63. doi:10.1016/j.ahj.2019.08.002
  12. Dawwas GK, Cuker A, Barnes GD, Lewis JD, Hennessy S. Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease : A Population-Based Study. Ann Intern Med . 2022;175:1506-1514. doi:10.7326/M22-0318
  13. Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban–an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32:183-187. doi:10.1007/s11239-011-0591-8
  14. Eliquis [Label] Princeton, NJ: Bristol-Myers Squibb; https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf. 2012
  15. Eliquis [European Union Summary of product characteristics]. European Medicines Agency. https://www.medicines.org.uk/emc/product/2878/smpc#gref. 2021.
  16. VanderPluym C, Esteso P, Ankola A, et al. Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease [published online ahead of print, 2023 Mar 14]. J Thromb Haemost. 2023;S1538-7836(23)00232-5. doi:10.1016/j.jtha.2023.03.005
  17. Buckley BJR, Lane DA, Calvert P, et al. Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. J Clin Med. 2022;11:3788. Published 2022 Jun 30. doi:10.3390/jcm11133788
  18. Beyer J, Trujillo T, Fisher S, Ko A, Lind SE, Kiser TH. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. Clin Appl Thromb Hemost. 2016;22(5):423-428. doi:10.1177/1076029616629759
  19. Bercovitz RS, Shewmake AC, Newman DK, et al. Validation of a definition of excessive postoperative bleeding in infants undergoing cardiac surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2018;155:2112-2124.e2. doi:10.1016/j.jtcvs.2017.12.038
  20. Moganasundram S, Hunt BJ, Sykes K, et al. The relationship among thromboelastography, hemostatic variables, and bleeding after cardiopulmonary bypass surgery in children. Anesth Analg. 2010;110:995-1002. doi:10.1213/ANE.0b013e3181cd6d20
  21. Niebler RA, Gill JC, Brabant CP, et al. Thromboelastography in the assessment of bleeding following surgery for congenital heart disease. World J Pediatr Congenit Heart Surg. 2012;3:433-438. doi:10.1177/2150135112447540
  22. Agarwal HS, Barrett SS, Barry K, et al. Association of blood products administration during cardiopulmonary bypass and excessive post-operative bleeding in pediatric cardiac surgery. Pediatr Cardiol. 2015;36:459-467. doi:10.1007/s00246-014-1034-z
  23. Pekelharing J, Furck A, Banya W, Macrae D, Davidson SJ. Comparison between thromboelastography and conventional coagulation tests after cardiopulmonary bypass surgery in the paediatric intensive care unit. Int J Lab Hematol. 2014;36:465-471. doi:10.1111/ijlh.12171
  24. Timpa JG, O’Meara LC, Goldberg KG, et al. Implementation of a Multidisciplinary Bleeding and Transfusion Protocol Significantly Decreases Perioperative Blood Product Utilization and Improves Some Bleeding Outcomes. J Extra Corpor Technol. 2016;48:11-18.
  25. Faraoni D, Van der Linden P. Factors affecting postoperative blood loss in children undergoing cardiac surgery. J Cardiothorac Surg. 2014 Feb 11;9:32. doi: 10.1186/1749-8090-9-32. PMID: 24512988; PMCID: PMC3924411.
  26. Gómez-Outes A, Alcubilla P, Calvo-Rojas G, et al. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. J Am Coll Cardiol. 2021;77:2987-3001. doi:10.1016/j.jacc.2021.04.061